The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
Loading...
Embargo End Date
ICR Authors
Authors
Mansur, MB
Ford, AM
Emerenciano, M
Ford, AM
Emerenciano, M
Document Type
Journal Article
Date
2017-12-01
Date Accepted
2017-10-18
Abstract
Childhood acute lymphoblastic leukaemia (ALL) with MLL rearrangement (MLL-r) is an aggressive disease still associated with a high mortality rate. Recent investigations have identified co-operating mutations in the RAS pathway and although the functional consequences of these mutations are not yet fully understood, aberrant regulation of RAS pathway signalling at both transcriptional and protein levels is observed. Studies investigating the efficacy of specific inhibitors of this pathway, e.g. MEK-inhibitors, have also achieved encouraging results. In this context, this mini-review summarizes the available data surrounding MLL-r infant ALL with RAS mutation in relation to other well-known features of this intriguing disease.
Citation
Biochimica et biophysica acta. Reviews on cancer, 2017, 1868 (2), pp. 521 - 526
Source Title
Publisher
ELSEVIER
ISSN
0304-419X
eISSN
1879-2561
Collections
Research Team
Biology of Childhood Leukaemia